Dr. Dale Mueller M.D.
Vice-Chairman of Cardiovascular Medicine, OSF SAINT FRANCIS MEDICAL CTR
Member of the Healthcare Council
Council Member Biography
Dale Mueller, MD, is a Cardiovascular and Thoracic Surgeon at Heartcare Midwest and Vice-Chairman of the Department of Cardiovascular Medicine and Surgery at OSF Saint Francis Medical Center in Illinois. He has expertise in cardiac surgery including minimally-invasive coronary bypass, valve repair and replacement; and thoracic and aortic aneurysms, including thoracic endoprosthesis, heart transplantation and ventricular assist devices. Dr. Mueller also has experience with thoracic surgery including thoracic oncology, laser bronchoscopy, endobronchial stents, and lung volume reduction surgery. His practice also encompasses vascular surgery including endovascular repair of abdominal aortic aneurysms, lower extremity bypass, carotid endarterectomy, and percutaneous vascular interventions and angiography. Dr. Mueller’s areas of clinical research include ventricular assist devices, coronary artery bypass, thoracic oncology, endovascular surgery, and minimally invasive surgery. (This is me - Update Profile)
Employment History
- 2003 - Unspecified
- Vice-Chairman of Cardiovascular Medicine, OSF SAINT FRANCIS MEDICAL CTR
- 1999 - 2003
- cardiovascular and thoracic surgeon, Illinois Cardiac Surgery Associates
- Unspecified - Unspecified
- Cardiovascular and Thoracic Surgeon, HEARTCARE MIDWEST SC
GLG NewsSM Analyses by Dale Mueller
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
December 4, 2006
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis | content.nejm.org
This study investigated carotid endarterectomy versus carotid stenting in patients with severe carotid stenosis. The study was stopped prematurely due to safety and futility. The 30-day incidence of stroke or death was 3.9% versus 9.6% for endarterectomy versus carotid stenting. This data implies that carotid stenting with cerebral protection is inferior to surgical endarterectomy, and therefore will not be as widely adopted as previous thought.
-
The forecast clears for drug eluding stents.
December 4, 2006
Trading restenosis for Thrombosis? New questions about drug-eluding stents. | content.nejm.org
This is a general commentary regarding coronary stent thrombosis and highlights the difficulties which Medtronic (Endeavor), Abbott (Xience V and Conor Medsystem (CoStar) may soon face with FDA approval of their new stents which are currently unavailable in the US. It also highlights that drug-coated stent sales have decreased while bare metal stents sales have accelerated.
-
Increased use of ventricular assist devices
December 4, 2006
Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart Failure | content.nejm.org
In a series of 15 patients, the Thoratec ventricular assist device was utilized with associated medical treatment for severe non-ischemic heart failure. Eleven of the fifteen patients recovered and avoided transplantation. Key implications include increased utilization of ventricular assist devices for the indication: "bridge to recovery." This could allow patients to avoid transplantation by temporary use of a left ventricular assist device.
-
Percutaneous valves: the future is upon us!
December 4, 2006
AHA Scientific Sessions - Percutaneous Devices for Aortic Valve Disease | www.cardiosource.com
Percutaneous valves are technically feasible.
Complications are currently not comparable to the traditional open valve replacement/repair. -
September 19, 2006
NEJM Articles on DES in MI | content.nejm.org
Implications:
- primary percutaneous interventions provide improved reperfusion therapy for acute myocardial infarction compared to thrombolysis
- many medical centers are focusing on the time it takes to actually perform PCI as a major focus for both patient care and a marketing technique
- Data are limited regarding the safety and efficacy of drug eluding stents in this setting, but they are clearly associated with an improved restenosis rate vs. uncoated bare metal stents
- The primary end point (target-vessel failure at 1 year after the procedure) was significantly reduced in the sirolimus-stent group compared to the uncoated stent group
- Drug eluding stents significantly reduce the risks of both restenosis and target-vessel revascularization after PCI due to acute myocardial infarction which could greatly expand the use of drug eluding stents
GLG Study Groups with Dale Mueller(?)
| Study Group Name | No. Members |
|---|---|
| General Cardiologists (US) | 1362 |
| Heart Failure Specialists (US) | 1084 |
| Physicians who Treat Hypertension (US) | 951 |
| Non-Electrophysiologist Cardiologists (US) | 849 |
| Cardiothoracic Surgeons (US) | 346 |
GLG Live Meetings with Dale Mueller(?)
Dale Mueller has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.